Insider Selling: Xencor (NASDAQ:XNCR) CEO Sells $72,798.12 in Stock

Xencor, Inc. (NASDAQ:XNCR) CEO Bassil Dahiyat sold 6,606 shares of the business’s stock in a transaction that occurred on Friday, March 6th. The stock was sold at an average price of $11.02, for a total value of $72,798.12. Following the transaction, the chief executive officer directly owned 546,316 shares in the company, valued at approximately $6,020,402.32. This trade represents a 1.19% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Xencor Stock Performance

XNCR opened at $12.04 on Thursday. Xencor, Inc. has a 12-month low of $6.92 and a 12-month high of $18.69. The stock has a market cap of $883.01 million, a price-to-earnings ratio of -9.71 and a beta of 0.95. The business has a 50 day moving average of $12.60 and a 200-day moving average of $13.05. The company has a quick ratio of 6.25, a current ratio of 6.25 and a debt-to-equity ratio of 0.12.

Xencor (NASDAQ:XNCR) last posted its earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.55. Xencor had a negative return on equity of 14.58% and a negative net margin of 73.20%.The business had revenue of $28.24 million for the quarter, compared to analyst estimates of $29.97 million. During the same period in the previous year, the firm earned ($0.62) EPS. The firm’s revenue was down 46.6% compared to the same quarter last year. On average, equities research analysts expect that Xencor, Inc. will post -3.68 earnings per share for the current year.

Institutional Investors Weigh In On Xencor

A number of institutional investors have recently modified their holdings of XNCR. Walleye Capital LLC bought a new position in Xencor during the second quarter worth about $1,955,000. Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in Xencor by 153.2% in the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 29,371 shares of the biopharmaceutical company’s stock valued at $231,000 after purchasing an additional 17,773 shares during the period. Squarepoint Ops LLC grew its position in shares of Xencor by 3,150.0% during the 2nd quarter. Squarepoint Ops LLC now owns 363,153 shares of the biopharmaceutical company’s stock worth $2,854,000 after purchasing an additional 351,979 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of Xencor during the 3rd quarter worth approximately $1,062,000. Finally, Primecap Management Co. CA increased its holdings in shares of Xencor by 1.4% during the third quarter. Primecap Management Co. CA now owns 10,675,022 shares of the biopharmaceutical company’s stock worth $125,218,000 after purchasing an additional 147,700 shares during the period.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Xencor in a research report on Monday, December 29th. Truist Financial began coverage on shares of Xencor in a report on Monday, November 24th. They set a “buy” rating and a $29.00 target price for the company. Wall Street Zen cut shares of Xencor from a “hold” rating to a “sell” rating in a report on Saturday, February 28th. Finally, Barclays raised their price objective on shares of Xencor from $26.00 to $27.00 and gave the stock an “overweight” rating in a research report on Thursday, February 26th. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Xencor has a consensus rating of “Moderate Buy” and a consensus target price of $25.00.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.